Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: Atutorial

PharmacoEconomics

Volumn 32, Issue 2, 2014, Pages 101-108

  Diaby, Vakaramoko ^a,b,c   Adunlin, Georges ^c   Montero, Alberto J ^d  

^a Research Institute   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c FLORIDA A AND M UNIVERSITY   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DECISION MAKING; DISEASE-FREE SURVIVAL; FEMALE; HEALTH RECORDS, PERSONAL; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MODELS, ECONOMIC; PROBABILITY;

EID: 84894029737     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0123-9     Document Type: Article

References (16)

1. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
2. Goeree R, Diaby V. Introduction to health economics and decision-making: Is economics relevant for the frontline clinician? Best Pract Res Clin Gastroenterol. 2013;27(6):831-44.
3. Latimer NR. Survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data: Inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743-54.
4. Piccart M, Baselga J, Noguchi S, Burris H, Gnant M, Hortobagyi G, et al. Final progression-free survival analysis of BOLERO-2: Aphase III trial of everolimus for postmenopausal women with advanced breast cancer [poster]. Cancer Res. 2012;72(24 Suppl.):492-3s (Abstract P6-04-02). Supplemental file available at: http://e-syllabus.gotoper.com/-media/-pdf/MBC13-P6-04-02-Piccart.pdf.
5. Stevenson M, Street R, Jones ML, Kearns B, Street S, Littlewood C, et al. Cabazitaxel for the second-line treatment of hormone refractory, metastatic prostate cancer: Asingle technology appraisal. ScHARR: The University of Sheffield; 2011.
6. Ghosh K, Tiwari RC. Nonparametric and semiparametric Bayesian reliability analysis. In: Ruggeri F, Kenett R, Faltin FW, editors. Encyclopedia of statistics in quality and reliability. Chichester, UK: Wiley; 2007. p. 1239-1248.
7. Coon JT, Hoyle M, Green C, Liu Z, Welch K, Moxham T, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: Asystematic review and economic evaluation. Health Technol Assess. 2010;14:1-208.
8. Rogers G, Hoyle M, Coon JT, Moxham T, Liu Z, Pitt M, et al. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: Asystematic review and economic evaluation. Health Technol Assess. 2012;16(22):1-410. doi: 10.3310/hta16220.
9. Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
10. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-9.
11. Qi JZ. Comparison of proportional hazards and accelerated failure time models. Dissertation, University of Saskatchewan; 2009. p. 89. Available at http://ecommons.usask.ca/bitstream/handle/10388/etd-03302009-140638/ JiezhiQiThesis.pdf.
12. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Contr. 1974;19(6):716-23.
13. Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6(2):461-4.
14. Moeschberger ML, Klein JP. Survival analysis: Techniques for censored and truncated data. Berlin: Springer; 2003.
15. Royston P, Lambert PC. Flexible parametric survival analysis using stata: Beyond the Cox model. College Station: Stata Press; 2011.
16. Jackson CH, Sharples LD, Thompson SG. Survival models in health economic evaluations: Balancing fit and parsimony to improve prediction. Int J Biostat. 2010;6(1):34.